Brief: Lytix Biopharma Q4 Loss Narrows To NOK 18.6 Mln
Feb 29 (Reuters) - Lytix Biopharma AS LYTIX.OL :
* Q4 LOSS FOR THE PERIOD NOK 18.6 MILLION VERSUS LOSS NOK
29.2
MILLION YEAR AGO
* Q4 TOTAL OPERATING INCOME NOK 5.1 MILLION VERSUS NOK 1.6
MILLION
YEAR AGO
* WHILE CURRENT CASH POSITION PROVIDES CASH RUNWAY THROUGH
H1
2024, CO CONTINUES TO EXPLORE STRATEGIC PARTNERING OPPORTUNITIES
Source text for Eikon: ID:nObibpvRRa
Further company coverage: LYTIX.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lytix Biopharma AS
See all newsBrief: Lytix Biopharma Q3 Loss Widens To NOK 23.3 Mln
Brief: Lytix Biopharma Announces Interim Data On Neoadjuvant Treatment Of Melanoma
Brief: Lytix Biopharma Q1 Operating Loss Narrows To NOK 13.4 Mln
Brief: Lytix Biopharma Q4 Total Operating Income Nok 377,000
Brief: Lytix Biopharma Gets Notice Of Allowance For US Patent Application For Ltx-315 Clinical Program